Nearly 30 million Americans have diabetes, 5 million Americans use insulin pumps, and 64% of diabetic users have experienced injection site malfunctions related to their insulin pumps.(1),(2),(3) Injection site malfunctions include insulin pump cannula blockage, improper insertion, and leakage of the medication from the infusion site. These malfunctions are life threatening to a diabetic user and no technology exists to effectively detect these described problems. DiaTech provides an innovative approach to create and implement a fluid pressure sensing device that optimizes insulin pump technology for patients with diabetes. This new device can notify the user via audio, visual and Bluetooth alerts when the insulin pump is malfunctioning, prompting the user to re-inject in a new location. We look to license or sell our intellectual property to a large medical company in an attempt to impact diabetes therapy on a global scale. The device can be produced for less than 1% of the price of an insulin pump and offers the purchasing company a technological advantage within the marketplace. Our solution could be universally integrated into insulin pumps within the market and a full patent is being pursued. This team is committed to improving the quality of life for people with diabetes.